Capstone Investment Advisors LLC Raises Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Capstone Investment Advisors LLC raised its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 90.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,062 shares of the biotechnology company’s stock after acquiring an additional 2,410 shares during the period. Capstone Investment Advisors LLC’s holdings in United Therapeutics were worth $1,163,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of the company. Advisors Asset Management Inc. raised its holdings in United Therapeutics by 1.9% during the 3rd quarter. Advisors Asset Management Inc. now owns 7,847 shares of the biotechnology company’s stock valued at $1,772,000 after buying an additional 143 shares during the period. Alps Advisors Inc. raised its holdings in United Therapeutics by 7.6% during the 3rd quarter. Alps Advisors Inc. now owns 1,495 shares of the biotechnology company’s stock valued at $338,000 after buying an additional 105 shares during the period. Schroder Investment Management Group raised its holdings in United Therapeutics by 21.5% during the 3rd quarter. Schroder Investment Management Group now owns 178,005 shares of the biotechnology company’s stock valued at $40,206,000 after buying an additional 31,510 shares during the period. iA Global Asset Management Inc. purchased a new stake in United Therapeutics during the 3rd quarter valued at $607,000. Finally, Mercer Global Advisors Inc. ADV raised its holdings in United Therapeutics by 22.6% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 12,151 shares of the biotechnology company’s stock valued at $2,745,000 after buying an additional 2,237 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Stock Up 1.1 %

Shares of UTHR traded up $3.52 during midday trading on Friday, reaching $314.56. 460,578 shares of the stock were exchanged, compared to its average volume of 607,684. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $325.00. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04. The company’s 50 day moving average is $282.72 and its two-hundred day moving average is $246.29. The company has a market capitalization of $13.95 billion, a P/E ratio of 14.87, a PEG ratio of 1.37 and a beta of 0.55.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The business had revenue of $677.70 million for the quarter, compared to the consensus estimate of $620.31 million. During the same quarter in the prior year, the company earned $4.86 EPS. The business’s revenue was up 33.7% compared to the same quarter last year. On average, sell-side analysts anticipate that United Therapeutics Co. will post 24.73 earnings per share for the current year.

Insider Activity at United Therapeutics

In related news, Director Nilda Mesa sold 266 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total transaction of $84,742.28. Following the sale, the director now owns 5,107 shares of the company’s stock, valued at $1,626,988.06. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Nilda Mesa sold 266 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total transaction of $84,742.28. Following the sale, the director now owns 5,107 shares of the company’s stock, valued at $1,626,988.06. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Christopher Causey sold 2,240 shares of the stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $259.91, for a total value of $582,198.40. Following the completion of the sale, the director now owns 4,185 shares of the company’s stock, valued at $1,087,723.35. The disclosure for this sale can be found here. Insiders have sold a total of 112,544 shares of company stock valued at $29,811,740 over the last quarter. 12.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Wells Fargo & Company increased their price target on United Therapeutics from $325.00 to $350.00 and gave the company an “overweight” rating in a report on Wednesday, June 12th. The Goldman Sachs Group increased their target price on United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. JPMorgan Chase & Co. increased their target price on United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 21st. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 20th. Finally, HC Wainwright reiterated a “buy” rating and issued a $300.00 target price on shares of United Therapeutics in a research note on Thursday, May 2nd. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $312.22.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.